Drug Type Small molecule drug |
Synonyms (-)-(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine, (-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine, 2-Methoxytrimeprazine + [21] |
Target |
Action antagonists |
Mechanism adrenergic receptor antagonists(Adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (27 May 1960), |
Regulation- |
Molecular FormulaC19H25ClN2OS |
InChIKeyODLGFPIWRAEFAN-PFEQFJNWSA-N |
CAS Registry1236-99-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Levomepromazine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Mood Disorders | Japan | 19 Jan 1963 | |
Bipolar Disorder | Japan | 27 May 1960 | |
Depressive Disorder | Japan | 27 May 1960 | |
Schizophrenia | Japan | 27 May 1960 | |
Behavioural disorders | United States | - |
Phase 3 | - | pzfwlrbqdt(cnlwwfzuna) = rgnxjghaoq mhwivtlsso (dvedxkoijn ) View more | - | 12 Sep 2019 | |||
pzfwlrbqdt(cnlwwfzuna) = zenwldliom mhwivtlsso (dvedxkoijn ) View more |